Navigation Links
Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia
Date:7/31/2014

An important step has been made to help better identify and treat those with fibromuscular dysplasia (FMD). FMD causes both an abnormal narrowing and enlarging of medium sized arteries in the body, which can restrict blood flow to the kidneys and other organs causing damage. In a new report appearing in August 2014 issue of The FASEB Journal, scientists provide evidence that that FMD may not be limited to the arteries as currently believed. In addition, they show a connection to abnormalities of bones and joints, as well as evidence that inflammation may be driving the vascular disease in FMD patients.

"Having medical treatment options for FMD, or for people who may be susceptible to FMD, will improve their quality of life by preventing vascular complications," said Nazli B. McDonnell, M.D., Ph.D., a researcher involved in the work from the National Institute on Aging at the National Institutes of Health in Baltimore, Maryland. "Recognizing the additional features of FMD, namely those involving the joints and bones, may help us to design better treatments for these ancillary symptoms that were previously thought to be independent of FMD."

To make this discovery, Nazli and colleagues recruited patients with FMD and performed physical exams. Vascular imaging and bone density studies were also conducted. Researchers measured specific proteins in the blood that indicated inflammation activation of the transforming growth factor-beta (or TGF-beta) pathway. Patient skin biopsies also were collected to grow dermal fibroblast cell lines, which were studied for TGF-beta pathway and inflammatory biomarkers and were compared to age-, sex-, and BMI-matched controls that did not have FMD.

"FMD is a serious blood vessel disease for which we know little," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "But this advance in basic science tells us that when we learn details how a relatively rare disease comes about, we learn more about others such as heart attacks, stroke and inflammatory arthritis."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Conservation scientists asking wrong questions on climate change impacts on wildlife
2. Scientists reproduce evolutionary changes by manipulating embryonic development of mice
3. 23andMe scientists receive approximately $1.4 million in funding from National Institutes of Health
4. Scientists discover genetic switch that can prevent peripheral vascular disease in mice
5. Scientists discover new, noncommittal mechanism of drug resistance
6. New tools help neuroscientists analyze big data
7. NIH scientists find 6 new genetic risk factors for Parkinsons
8. NYSCF scientists one step closer to cell therapy for multiple sclerosis patients
9. NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients
10. NUS scientists use low cost technique to improve properties and functions of nanomaterials
11. Mount Sinai scientists and international team shed new light on schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® ... provides a free webinar on Performing Quality Investigations: Getting to Root ... CT at no charge. , Incomplete investigations are still a major concern to ...
Breaking Biology Technology: